Guidance Update

Amid soaring aerospace demand and strong financials, the critical component supplier will outline its tech and market strategy at its March 10 investor day.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Investors sue medical device maker Integer Holdings, alleging misleading statements led to a catastrophic 32% stock drop. What went wrong behind the scenes?

Budget carrier Avelo Airlines extends its Central Florida schedule through summer 2026, offering low fares and doubling down on its regional strategy.

After six decades, Daiwa Capital Markets America is accelerating its U.S. expansion with a new HQ, new products, and a major hiring push.

A contractor's death in Côte d’Ivoire raises tough questions about safety oversight in the mining supply chain, challenging Perseus Mining's strong record.

CVS Health is set to reveal its 2025 results. Will its integrated strategy pay off amid rising costs, PBM scrutiny, and a key Aetna turnaround?

ChipMOS reports stunning 20.8% Q4 growth, highlighting a memory chip frenzy fueled by AI and datacenters. Is this the start of a new tech supercycle?

A breakthrough liquid biopsy shows over 80% accuracy in finding feline lymphoma, offering a non-invasive screening tool for vets and hope for cat owners.

Pan Global Resources has defined a major copper and gold resource in Spain, fueling the green energy transition and reviving a historic mining district.

A new forecast warns of sub-1% growth as tariffs, labor shifts, and debt create an era of experimentation, urging investors to adapt and diversify.

A new partnership combines 3D depth with panoramic visuals, creating an unparalleled movie experience. But is it enough to win the premium cinema war?

A $170M deal to boost infant formula supply has soured for Perrigo, leading to a 25% stock crash, a strategic review, and securities fraud lawsuits.